Search research articles
Contact Us
Filters
Showing results (161-170 of 207) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
JCO Precision Oncology
|
April 20, 2023
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report
Theresa Reutter, Jana Fassunke, Michael Püsken, et al.
JTO Clinical and Research Reports
|
March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition
Richard Riedel, Lea Ruge, Malte Verheyen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2024
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
Anna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 30, 2024
Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158]
Anna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses
Lea Ruge, Felix John, Malte Verheyen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 14, 2023
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Moritz Glaser, Anna Rasokat, Darinka Prang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2018
Clinical and Pathological Characteristics of <i>KEAP1</i>- and <i>NFE2L2</i>-Mutated Non-Small Cell Lung Carcinoma (NSCLC)
Rieke Frank, Matthias Scheffler, Sabine Merkelbach-Bruse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
Matthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 207) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
JCO Precision Oncology
|
April 20, 2023
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report
Theresa Reutter, Jana Fassunke, Michael Püsken, et al.
JTO Clinical and Research Reports
|
March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition
Richard Riedel, Lea Ruge, Malte Verheyen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2024
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
Anna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 30, 2024
Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158]
Anna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses
Lea Ruge, Felix John, Malte Verheyen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 14, 2023
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Moritz Glaser, Anna Rasokat, Darinka Prang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2018
Clinical and Pathological Characteristics of <i>KEAP1</i>- and <i>NFE2L2</i>-Mutated Non-Small Cell Lung Carcinoma (NSCLC)
Rieke Frank, Matthias Scheffler, Sabine Merkelbach-Bruse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
Matthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Page
of 21